Phio Pharmaceuticals Completes PH-762 Phase 1b Trial with Favorable Data, Targets Q2 FDA Submission

summarizeSummary

Phio Pharmaceuticals announced the completion of its Phase 1b clinical trial for lead candidate PH-762 with favorable data, setting the stage for an FDA submission in Q2 2026 to advance the skin cancer treatment.

check_boxKey Events

• PH-762 Phase 1b Trial Completed

  Phio Pharmaceuticals announced the successful completion of its Phase 1b dose-escalation clinical trial for PH-762, its lead candidate for the treatment of cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma.

• Favorable Safety and Pathology Data

  Preliminary analysis of the trial data indicates favorable safety and pathology results, with final data analysis ongoing.

• Q2 2026 FDA Submission Targeted

  The company plans an FDA submission in Q2 2026 to propose and seek guidance for the next steps in the PH-762 clinical study design.

• Q1 2026 Financials Reported

  The company reported a net loss of $4.0 million for the three months ended March 31, 2026, a significant increase from $1.8 million in the prior year, primarily due to higher R&D and G&A expenses.

auto_awesomeAnalysis

This 8-K provides a significant update on Phio Pharmaceuticals' lead clinical candidate, PH-762, announcing the successful completion of its Phase 1b dose-escalation trial for skin cancer. The company reported favorable safety and pathology data, a crucial step for a clinical-stage biopharmaceutical firm. The next key milestone is an FDA submission in Q2 2026 to determine the path forward for the PH-762 development program. While the filing also reiterates previously disclosed Q1 2026 financial results (which showed a wider net loss and increased expenses, already covered by a concurrent 10-Q) and an existing ATM program, the clinical progress is the primary market-moving information.